The company generates zero revenue while incurring quarterly administrative overhead costs that reached $168.3K in 2026Q1.
| Sales/Revenue | 0 | - | - |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | - | - |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 531.06K | 569.11K | 177.4K |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 737.38K | 569.11K | 177.4K |
| SG&A % of Revenue | - | - | - |
| Research & Development | 0 | - | - |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 0 | - | - |
| Operating Income | -531.06K | -569.11K | -177.4K |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -220.81% | - |
| EBITDA | -531.06K | -569.11K | 381.08K |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | -249.34% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 |
| EBIT | -531.06K | -569.11K | 381.08K |
| Net Interest Income | -296.37K | 9.68M | 558.48K |
| Interest Income | -296.37K | 9.68M | 558.48K |
| Interest Expense | 0 | 0 | 0 |
| Other Income/Expense | 0 | - | - |
| Pretax Income | 8.86M | 9.12M | 381.08K |
| Pretax Margin % | - | - | - |
| Income Tax | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% |
| Net Income | 8.86M | 9.12M | 381.08K |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 2292.03% | - |
| Net Income (Continuing) | 8.86M | 9.12M | 381.08K |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | 0.39 | 0.31 | 0.01 |
| EPS Growth % | - | 2303.1% | - |
| EPS (Basic) | - | 0.31 | 0.01 |
| Diluted Shares Outstanding | 23M | 23M | 29.59M |
| Basic Shares Outstanding | 23M | 23M | 29.59M |
| Dividend Payout Ratio | - | - | - |
Liquidation and deal failure
As reported in recent financial filings, JACS maintains a consistent quarterly SG&A burn rate, with expenses reaching $168.3K in 2026Q1, reflecting the ongoing costs of maintaining a public shell entity without any offsetting revenue streams to mitigate the erosion of its limited cash reserves.
The company's cost structure is entirely comprised of administrative overhead, which is typical for a pre-combination SPAC. Investors should monitor whether these recurring expenses necessitate additional sponsor loans, as the current cash position provides little buffer for extended search periods.
Based on the provided income statement data, JACS reported a net income of $2.0M in 2026Q1, a figure that appears disconnected from its operational reality and likely stems from non-operating items such as interest income or adjustments related to warrant liabilities rather than core business performance.
The divergence between persistent operating losses and positive net income suggests that the bottom line is highly sensitive to non-cash accounting adjustments. Analysts should treat these earnings as non-recurring and focus instead on the underlying cash burn rate to assess the company's true financial health.
According to historical performance data, the sponsor's previous vehicle, P3 Health Partners, experienced significant share price depreciation, which may indicate that JACS's current search process is burdened by a negative reputation that could hinder its ability to secure high-quality merger targets or favorable financing terms.
The pressure to execute a deal before the liquidation deadline may force management into suboptimal acquisitions to avoid returning capital to shareholders. This structural urgency warrants further investigation into whether the sponsor's deal-sourcing network can actually deliver value or if it merely facilitates a high-risk transaction.
Quick answers to the most common questions about buying JACS stock.
Jackson Acquisition Company II (JACS) is profitable, generating $9.1M in net income for the fiscal year ending 2025.